Back to School: How biopharma can reboot drug development. Access exclusive analysis here
A French Phase IIa trial in 24 patients with GERD that showed 250 mg oral ADX10059 reduced the number of symptomatic episodes vs.
Sign in to your BioCentury account to access your content.
Get a two-week free trial subscription to BioCentury